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Abstract
The clinical diagnosis of mould infections currently involves complex species identification based on morphological criteria, which is often
prone to error. Employing an extensive mould species reference spectral library (up to 2832 reference spectra, corresponding to 708
strains from 347 species), we assessed the extent to which matrix-assisted laser desorption ionization time-of-flight mass spectrometry
(MALDI-TOF MS) enhanced the accuracy of species identification. MALDI-TOF MS data were validated against morphology-based and
DNA sequence-based results with 262 clinical isolates collected over a 4-month period in 2013. The implementation of MALDI-TOF MS
resulted in a dramatic improvement in mould identification at the species level (from 78.2% to 98.1%) and a marked reduction in the
misidentification rate (from 9.8% to 1.2%). We then compared the mould identification results obtained before (i.e. 2011) and after (i.e.
2013) the implementation of MALDI-TOF MS in routine identification procedures, which showed an improvement from 64.57% to 100%.
Reassessment of a set of isolates from 2011 with this procedure, including MALDI-TOF MS, yielded an increase in species diversity from 16
to 42 species. Finally, application of this procedure during a 16-month period (2012–2013) enabled the identification of 1094 of 1107
(98.8%) clinical mould isolates corresponding to 107 distinct species. MALDI-TOF MS-based mould species identification may soon
challenge traditional techniques in the clinical laboratory, as patient prognosis is largely contingent on rapid and accurate diagnosis.
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Introduction
Over the past few years, matrix-assisted laser desorption
ionization time-of-flight mass spectrometry (MALDI-TOF MS)
has revolutionized the identification of bacteria and yeast in
the laboratory setting [1]. This technique enables the gener-
ation of protein spectra for any given microorganism, which
can be used for the identification of the microorganism by
comparing the spectrum results with a reference spectral
library. As MALDI-TOF MS-based identification is highly
reliable and easy to perform, it is currently replacing traditional
microbiological methods for the identification of bacteria and
yeasts in a growing number of clinical laboratories [2].
ExtendingMALDI-TOF MS-based technology tomould iden-
tificationwould be ofmajor clinical interest [3]. Indeed, the rates
of certain mould infections, such as aspergillosis, fusariosis, and
mucormycosis, have increased [4–6]; for these infections, poor
prognosis is associated with an extended time of diagnosis [7]. In
medical laboratories, mould identification requires highly skilled
mycologists, who base their diagnoses onmorphological aspects
of fungal colonies andmicroscopic examination of the structures
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bearing spores and the spores themselves [8]. Although DNA
sequencing may complete morphological identification, in the
real world the results of routine mould identification are often
imprecise and prone to frequent errors [9].
As several recent publications have shown that
MALDI-TOF MS-based identification of many mould species
is feasible [10–13], we established an extensive reference
spectral library and incorporated it into a routine mould
identification procedure. We validated the accuracy of
MALDI-TOF MS in comparison with both morphology and
DNA sequencing. We then compared the identification results
obtained during two 4-month periods, before and after the
inclusion of MALDI-TOF MS-based analysis in the identifica-
tion procedure. Finally, the systematic implementation of our
novel identification procedure on a consecutive series of
23 290 clinical samples, of which 1115 yielded the growth of
mould colonies, provided the opportunity to appreciate the
manner in which MALDI-TOF MS enhanced the identification
of mould pathogens, including many emerging species.
Materials and Methods
Study design
In this study, we used a three-step approach. First, all isolates
identified between 1 January and 30 April 2013 during routine
laboratory analyses were subjected to both
MALDI-TOF MS-based and morphology-based identification,
and the results were then compared with the DNA sequence--
based identification data. For the four most frequently observed
species (i.e. Aspergillus fumigatus, Aspergillus flavus, Aspergillus
niger, andAspergillus terreus), DNAsequence-based identification
was performed on only one in ten isolates for quality control.
In the second step, we compared the identification perfor-
mance achieved in 2013 with that obtained between 1 January
and 30 April 2011 (i.e. before MALDI-TOF MS-based identi-
fication was included in routine laboratory analyses), with a
focus on the percentage of successful identifications at the
species level and the diversity of species. We then subcultured
all available isolates collected from 1 January 2011 to 30 April
2011, which were stored at 20°C, and performed isolate
re-identification with MALDI-TOF MS.
In the third step, we analysed the results of our new
identification procedure applied to all clinical mould isolates
assessed during routine laboratory activity between 1 January
2012 and 30 April 2013.
Identification procedure
All clinical samples were inoculated onto Sabouraud Genta-
micin Chloramphenicol agar plates (Oxoid, Dardilly, France),
and each growing mould colony was subjected to identifica-
tion. Before 2012, the routine identification of mould samples
relied on the analysis of macroscopic and microscopic
morphological features by senior mycologists, according to
an identification key described by de Hoog et al. [8]. When the
mycologists deemed it necessary, DNA sequence identification
was performed, based on sequence analysis of the D1–D2
variable region of the 28S gene and the ITS2 region of the
rRNA gene [14,15].
From January 2012, all mould samples isolated from routine
specimens were also subjected to MALDI-TOF MS-based
identification with a Microflex LT mass spectrometer (Bruker
Daltonics, Bremen, Germany), as described by Cassagne et al.
[13]. Briefly, as soon as cultures grew, generally within 2 or
3 days, mould samples were deposited onto the
MALDI-TOF MS target in four replicates after formic acid
and acetonitrile pretreatment. The spectra obtained were
compared with those in the in-house mould reference spectral
library by the use of MALDI Biotyper 3.0 software (Bruker
Daltonics). As described by Normand et al. [12], each
reference strain was subcultured on four Sabouraud Genta-
micin Chloramphenicol agar plates (Oxoid) at 30°C, and
analysed after 72 h of culture. The library contained 2832
spectra corresponding to 708 strains (four spectra each) of
347 distinct species, as listed in Data S1. All isolates included
in the library were identified with morphology-based and
multilocus sequence-based identification: both the D1–D2
variable region of the 28S gene and the ITS2 region of the
rRNA gene were sequenced [14,15]. Partial sequence analysis
of the calmodulin-encoding and b-tubulin-encoding genes was
also carried out for Aspergillus species and Penicillium species
identification [16]. Sequencing of the elongation fac-
tor 1-encoding gene was performed to identify Fusarium and
Alternaria species [17]. The reference strains remain conserved
in the BCCM/IHEM collection. According to Cassagne et al.
[13], the MALDI-TOF MS-based identification of samples was
considered to be valid if at least three of the four identifica-
tions obtained for the four deposited replicates corresponded
to the same species, and the similarity score (log score) was
≥1.9 for at least one of these four replicates. If the
MALDI-TOF MS-based identification was not validated, it
was performed a second time. DNA sequence-based identi-
fication was performed with the same protocol as used for
species included in the MALDI-TOF MS reference database,
when MALDI-TOF MS-based identification failed twice and
when morphology-based and MALDI-TOF MS-based identifi-
cation were discordant. DNA sequence-based identification
was also carried out for relatively rare species. We sequenced
54 of 247 isolates in the second step, and 259 of 1107 isolates
in the third step.
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Statistical tests
Qualitative variables were described as percentages and
95% CIs, and then compared by use of the Fisher exact test.
Quantitative variables were described as the mean and
standard deviation, and then compared by the use of ANOVA.
Statistical analyses were performed with SPSS 15.0 statistical
software [18]. All statistical tests were two-sided, and a
p-value of <0.05 was considered to be statistically significant.
Results
Between 1 January and 30 April 2013, 6531 samples were
received and cultured, 262 (4%) of which yielded growth of
mould isolates. Morphological identification at the species level
was achieved for 205 isolates (78.2%); the remaining isolates
could either not be identified or were identified only at the
genus level. MALDI-TOF MS-based identification at the spe-
cies level was achieved for 257 isolates (98.1%) after one (243/
257) or two (14/257) runs. The five isolates that were not
identified with MALDI-TOF MS could also not be identified
with morphology; only DNA sequencing enabled species
identification of these isolates (A. fumigatus, Aspergillus fumigat-
iaffinis, Aspergillus insulicola, Penicillium cecidicola, and Macropho-
mina phaseolina). The identified species was not included at the
time of analysis, with the exception of the A. fumigatus isolate.
Among the 257 isolates identified with MALDI-TOF MS,
182 were identified as A. fumigatus, A. flavus, A. niger and
A. terreus with both MALDI-TOF MS-based and morphol-
ogy-based assessment. The isolates subjected to DNA
sequence-based identification for quality control showed
concordant results in each case. DNA sequencing could be
performed for 68 of the 75 isolates belonging to other
species. We could not perform DNA sequencing for five
isolates, as the subculture either did not grow or was
contaminated, and DNA sequence-based identification was
not accurate enough to discriminate between several species
in two isolates. These results confirmed the morphol-
ogy-based and MALDI-TOF MS-based identification of the
45 isolates. The results also highlighted morphological
misidentification of the 20 isolates for which MALDI-
TOF MS-based and morphology-based identification were
discordant (Table 1). Finally, three MALDI-TOF MS-based
identification errors were identified: one Aspergillus quadri-
lineatus isolate, one Penicillium diversum isolate, and one
Penicillium roquefortii isolate, which were eventually identified
with MALDI-TOF MS as Aspergillus nidulans, Penicillium funi-
culosum, and Penicillium chrysogenum, respectively.
The results of routine identification carried out during the
first 4 months of 2011 and during the same period of 2013 (i.e.
before and after implementation of MALDI-TOF MS-based
identification, respectively) are shown in Table 2. The data
show a dramatic improvement in identification at the species
level in 2013 (i.e. 100% in 2013 vs. 64.6% in 2011, p <104) and
an increase in species diversity (38 and 27 distinct species in
2013 and 2011, respectively). Among the 302 isolates identi-
fied in 2011, 247, including 82 for which the species was not
identified with morphology-based analysis in 2011, could be
recultured and re-identified with MALDI-TOF MS-based
analysis. These results are shown in Table 3. Briefly, 241
(97.6%) isolates were identified at the species level with
MALDI-TOF MS-based analysis after one run (229/241) or
two runs (12/241). Overall, species diversity increased from 16
in 2011 to 42 after re-identification.
TABLE 1. Details of the clinical mould isolates that were
misidentified on the basis of morphological features, between
1 January and 30 April 2013
Morphology-based
identification n
MALDI-TOF MS-based
identificationa
Aspergillus niger (n = 7) 7 Aspergillus tubingensis
Aspergillus versicolor (n = 3) 3 Aspergillus sydowii
Aspergillus fumigatus (n = 3) 2 Aspergillus fischerianus
1 Aspergillus hiratsukae
Aspergillus nidulans (n = 1) 1 Aspergillus nidulans var. echinulatus
Aspergillus ustus (n = 3) 3 Aspergillus calidoustus
Aspergillus terreus (n = 3) 2 Aspergillus hortai
1 Aspergillus alabamensis
MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass
spectrometry.
aEach MALDI-TOF MS-based identification was confirmed with DNA sequencing.
TABLE 2. Comparison of the routine mould identification
results obtained during two 4-month periods before (i.e.
2011) and after (i.e. 2013) the inclusion of MALDI-
TOF MS-based analysis in the identification procedure
2011 2013 p
Samples (n) 5138 6531
Isolates (n) 302 262
Frequency of morphology-based identification
n, ratio (%)
(95% CI)
185, 61.26
(55.51–66.78)
205, 78.24
(72.75–83.09)
<104
Frequency of morphology-based misidentification
n, ratio (%)
(95% CI)
14, 8.48a
(4.72–13.83)
21, 10.24
(6.45–15.23)
0.565
Frequency of MALDI-TOF MS-based identification
n, ratio (%) (95% CI) Not done 257, 98.09
(95.60–99.38)
–
DNA sequence-based
identification (n)
10 5 0.302
Total identification frequency
n, ratio (%) (95% CI) 195, 64.57b
(58.89–69.96)
262, 100
(98.60–100)
<104
Frequency of species-level identification failure
n, ratio (%)
(95% CI)
107, 35.43b
(30.04–41.11)
0, 0.00
(0.00–1.40)
<104
Fungal diversity
(no. of species)
27 38 –
Aspergillus diversity
(no. of species)
10 16 –
MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass
spectrometry.
aConcerns 165 isolates for which morphology-based identification at the species
level was confirmed with DNA sequence-based analysis.
bIn 2011, at diagnosis.
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From the 23 920 clinical samples assessed in our routine
practice laboratory between 1 January 2012 and 30 April 2013,
1115 mould isolates were obtained, primarily from respiratory
clinical samples (90%). The identification procedure was
correctly applied in all cases except for eight isolates (0.7%)
that were excluded. The final identification rate was 98.8%
(1094 of 1107 isolates). Specifically, 1015 isolates were
identified with MALDI-TOF MS-based analysis after one run
(914/1107) or two runs (101/1107), and 79 isolates were
identified with DNA sequence-based analysis after
MALDI-TOF MS failure. Identification exclusively at the genus
level was achieved for 11 isolates (Penicillium species, eight
isolates; Alternaria species, one isolate; Antrodia species, one
isolate; and Paecilomyces species, one isolate), and failed for
two isolates (0.2%, Agaricomycetes).
Interestingly, fungal flora showed large variations according
to patient origin (Fig. 1). Overall, 107 distinct species belonging
to 34 genera were identified. The most common filamentous
fungus was A. fumigatus (43.4%), followed by A. flavus (11.1%),
A. niger (5.1%), A. terreus (4.5%), P. chrysogenum (4.2%), and
Aspergillus tubingensis (3.0%). The last of these species emerged
as the sixth most frequent mould species isolated from clinical
samples, primarily from respiratory samples. We also identi-
fied dematiaceous fungi (such as Cochliobolus hawaiiensis) and
Basidiomycetes (such as Schizophyllum commune), which are
species that could not be identified according to morphological
criteria in the routine clinical laboratory setting.
Discussion
Our study highlights the extensive progress made in the mould
identification process with the introduction of MALDI-
TOF MS into routine laboratory analyses. The current findings
also demonstrate that mould identification was far from
satisfactory prior to MALDI-TOF MS implementation. In 2011,
with morphological identification criteria, only 63.1% of
samples could be identified at the species level. In fact, species
identification of moulds with morphological criteria is com-
plex, and new fungal species are continuously being described.
For instance, Hendrickx et al. [19] found that 51% of the
clinical isolates of Aspergillus section nigri stored in their
collection had been initially misidentified. Balajee et al. found
that 24% of slowly sporulating clinical A. fumigatus isolates
were Aspergillus lentulus, a species showing reduced suscepti-
bility to amphotericin B, voriconazole, and caspofungin [20,9].
In contrast to morphology-based analysis, MALDI-
TOF MS-based analysis enabled the identification of 98.1% of
the isolates in 2013. Among the growing number of studies
concerning MALDI-TOF MS-based identification of fungi, only
a few have tested a substantial number of mould isolates (i.e. at
least 100 isolates) [3]. Lau et al., DeCarolis et al. and Cassagne
et al. identified 88.7%, 88.3% and 87% of mould isolates,
respectively [10,13,21]. Regarding non-Aspergillus species,
Ranque et al. [22] doubled the number of isolates identified
with MALDI-TOF MS-based analysis relative to morphol-
ogy-based analysis. All of these studies were conducted with
a Microflex LT or Ultraflex mass spectrometer and a
home-made library. The manufacturer library was tested only
by Lau et al., who showed an increase from 0.7% to 88.9% of
mould isolates identified with a home-made library rather than
the library provided by the manufacturer. The low accuracy
rate of the manufacturer database convinced us to generate
our own library. The current study demonstrates that use of
an appropriate reference spectral library plays a major role in
enhancing mould identification. Further progress is expected
as the reference spectral library is continuously updated. The
increased proportion of successful MALDI-TOF MS-based
identifications has enabled us to devote more resources to
identifying the remaining unidentified specimens by increasing
the number of analysed DNA targets for DNA sequence-based
identification [23]. This resulted in the identification of a
significantly increased diversity of mould species. Although it is
exciting, this dramatic increase in the variety of identified
mould species may complicate clinical interpretation. Indeed,
accurate mould identification appropriately guides the treat-
ment of infections caused by species resistant to antifungal
medications [24]. However, the clinical significance of this
TABLE 3. Comparison between the initial identification
results obtained in 2011, without MALDI-TOF MS, and those
obtained after application of MALDI-TOF MS in 2013, for 247
routine clinical mould isolates that were recultivated and
re-identified
Initial identification
results (2011) Re-identification results (2013)
Total identification frequency
n, ratio (%)
(95% CI)
165, 66.8 (60.6–72.6) 244a, 98.8 (96.5–99.8)
Frequency of species-level identification failure
n, ratio (%)
(95% CI)
82, 33.2 (27.4–39.5) 3, 1.12 (0.25–3.51)
Frequency of MALDI-TOF MS-based identification
n, ratio (%)
(95% CI)
Not done 241, 97.6 (94.8–99.1)
Fungal diversity
(no. of species)
16 42b
MALDI-TOF MS, matrix-assisted laser desorption ionization time-of-flight mass
spectrometry.
aIncluding three isolates identified exclusively with DNA sequencing.
bIncluding 26 species not identified in 2011: Alternaria malorum, Aspergillus
calidoustus, Aspergillus hortai, Aspergillus lentulus, Aspergillus puniceus, Aspergillus
sclerotiorum, Aspergillus tubingensis, Fusarium oxysporum, Fusarium proliferatum,
Fusarium solani, Fusarium verticillioides, Paecilomyces lilacinus, Penicillium allii, Penicillium
aurantiogriseum, Penicillium citrinum, Penicillium crustosum, Penicillium funiculosum,
Penicillium griseofulvum, Penicillium madriti, Penicillium nalgiovense, Penicillium piceum,
Penicillium pinophilum, Penicillium purpurogenum, Phaeoacremonium parasiticum,
Trichoderma longibrachiatum, and Ulocladium oudemansii.
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ground-breaking identification accuracy may be debated in
other cases.
In this respect, we have found that the mould species
distribution differed according to the nature of the sample
and hospitalization ward, which probably reflects the base-
line condition of the patient. For instance, the broad
diversity of species involved in fungal airway colonization
in patients with cystic fibrosis or other chronic respiratory
diseases contrasted sharply with the low number of positive
samples and the few species recovered from patients with
haematological diseases. A variety of species, including
Aspergillus fischerianus, Aspergillus alabamensis, Aspergillus hor-
tai, Aspergillus calidoustus, and A. tubingensis, which cannot be
identified with conventional identification procedures in the
clinical laboratory, proved to be involved in chronic
bronchial airway colonization. This highlights the limitations
of previous studies aimed at describing fungal airway
colonization in cystic fibrosis patients, which have usually
focusds on A. fumigatus [25] or the Scedosporium species
complex [26], thereby providing a biased representation of
the true fungal flora of the patient airway. Similarly, in ear,
nose and throat ward patients, not only were A. fumigatus
and A. niger detected, but so were rarer species, such as
S. commune, C. hawaiiensis, and Acremonium strictum [27]. The
clinical significance of these emerging fungal species, which
have rarely been reported in Europe, must be examined
further [28,29].
In addition to the ability of MALDI-TOF MS to enhance
identification accuracy, the method proved to be rapid and
rather simple to perform. Tan et al. [30] showed that
bacteria and yeasts were identified 1.45 days earlier with
MALDI-TOF MS than with standard protocols. In our
experience, the time required for analysis (taking into
account pretreatment and interpretation) is approximately
95 min for a series of 24 isolates. Furthermore, even young
colonies could be accurately identified, before the appearance
of certain characteristics that morphological identification is
based on. Reducing the time required for mould identification
in routine analysis is of major clinical interest, as patient
prognosis worsens as the time prior to initiation of
appropriate therapy increases [7].
Overall, the capacity to better discriminate between
species will undoubtedly result in an improvement in the
service provided by the laboratory to physicians. With the
ongoing establishment of mass spectrometry technology in
routine laboratories, it is likely that the microscopy-based
identification of moulds in the clinical setting will be either
challenged or completed by the MALDI-TOF MS-based
approach, as has already occurred in the field of bacteriology.
Currently, both methods are applied in parallel in our
laboratory, with DNA sequence-based identification being
used when necessary.
Acknowledgements
We thank S. Moore for proofreading the manuscript.
Transparency Declaration
None.
FIG. 1. The numbers of clinical samples
received during a 16-month survey for
mycological analysis are represented by
bars, grouped according to hospital ward.
n = number of filamentous fungi isolated
in the laboratory. The pie charts illustrate
the distribution of the principal mould
species routinely identified with the
procedure including matrix-assisted laser
desorption ionization time-of-flight mass
spectrometry-based identification.
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Data S1. Composition of the in-house mould reference
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